OTD is a CRO focused on oncology, specialised in the anticancer drugs.
OTD is a small and flexible team – our team is composed of MD, PhD or MSc) with a collective experience managing over 60 Phase I-II oncology clinical trials, and fully committed to quality and transparency.
The client benefit is to fully achieve the objectives and in the fastest possible time.
We provide the following services:
- Protocol Writing & e-CRF Design
- Regulatory Applications
- Project Management
- PV
- Monitoring
- Data Management (preferred vendor)
- Report and Publications writing
OTD unique approach:
- Our Tactics: OTD’s medical oncologists closely review every patient “hands-on and in real-time”, while there is still time to address eligibility, toxicity and dosing issues.
- Special resources: Access to leading Principal Investigators and unique patient populations worldwide.
We have a specificity our experience in Phase I First-in Man managing clinically relevant information, analysis and transfer to Sponsor.
Tumour types and therapies
Solid tumours: Bladder, breast, cholangiocarcinoma, colorectal, glioblastoma, head & neck, hepatoma, lung, melanoma, ovary, pancreatic, prostate, renal, sarcomas, stomach, thyroid, and rare tumour types (eg, NMC)
Hematologic malignancies: leukaemia (ALL, AML), Hodgkin’s and non-Hodgkin’s lymphomas, β-hemoglobinopathies (SCA and β-thalassemia major), myeloproliferative disorders
Monotherapy / Combinations: classic cytotoxics, targeted therapeutic agents (small molecules and monoclonal antibodies), hormonal therapies, cell-based therapies, vaccines.
For more information on what OTD can offer you, please fill out the enquiry form attached to this page.
Make an enquiry
Thank you for submitting the form. Your enquiry will be submitted to the company.